Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2023-01-18 Director's Dealing
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2023-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-18 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-11 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-10 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company posted a corporate presentation at the 41st Annual J.P. Morgan Health Care Conference and provides preliminary financial information. The document includes an excerpt from the corporate presentation as an exhibit. The length of the document is 4155 characters, which is relatively short and mainly serves as an announcement of the presentation and preliminary results rather than the full presentation or detailed financial report itself. The document explicitly states that the information is preliminary and unaudited, and the presentation is attached as an exhibit. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full financial report or detailed financial statements. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-01-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.